神经病理性疼痛成分可预测疼痛性肿瘤放疗后疼痛干扰改善:一项前瞻性观察性研究的二次分析
该研究为前瞻性观察性研究的二次分析,纳入302例因疼痛性肿瘤接受放疗的患者,其中93例(31%)的索引疼痛被诊断为具有神经病理性成分。多变量线性回归分析显示,在2个月随访时,有神经病理性成分的患者在行走能力(p=0.048)、正常工作(p=0.021)、睡眠(p=0.001)和生活乐趣(p=0.010)方面的疼痛干扰评分较无此成分者改善更显著。结论认为神经病理性疼痛成分可预测放疗后疼痛干扰的更大改善。
要点
- 302例可分析患者中93例(31%)的索引疼痛具有神经病理性成分。
- 2个月随访时,有神经病理性成分者行走、工作、睡眠、生活乐趣的疼痛干扰改善优于无此成分者。
- 作者认为,具有神经病理性肿瘤相关疼痛的患者应被提供接受姑息性放疗的选项。
核心结论
- 神经病理性疼痛成分的存在可预测放疗后疼痛干扰的更大改善。
- 作者认为,具有神经病理性肿瘤相关疼痛的患者应被提供接受姑息性放疗的选项。
研究设计与样本
- 本研究为前瞻性观察性研究的二次分析,纳入因疼痛性肿瘤计划接受放疗的患者。
- 在放疗开始时及此后1、2、3个月收集简明疼痛评估量表数据。
- 采用多变量线性回归分析神经病理性成分对疼痛干扰评分变化(随访值减基线值)的影响,使用10个协变量作为潜在混杂因素。
- 共302例可分析患者,其中93例(31%)的索引疼痛被诊断为具有神经病理性成分。
主要发现
- 多变量线性回归分析显示,1、2、3个月随访时回归系数的所有点估计值均为负值,部分具有统计学显著性。
- 2个月随访时,有神经病理性成分的患者较无此成分者在行走能力(p=0.048)、正常工作(p=0.021)、睡眠(p=0.001)和生活乐趣(p=0.010)方面的疼痛干扰评分改善更大。
临床怎么用
- 作者认为,具有神经病理性肿瘤相关疼痛的患者应被提供接受姑息性放疗的选项。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: We previously demonstrated that patients with a tumor-related neuropathic pain component were more likely to experience a pain response after radiotherapy (RT) than those without. It is unknown whether the presence of a neuropathic component also favorably influences pain interference. In a secondary analysis of our previous prospective observational study, we investigated if the presence of a neuropathic component of the index pain caused by the irradiated tumors predicts greater reduction in pain interference. MATERIAL AND METHODS: For patients scheduled for RT for painful tumors, Brief Pain Inventory data were collected at initiation of RT and 1, 2, and 3 months thereafter. Multivariable linear regression analyses were performed to investigate the effects of the presence of a neuropathic component on the changes in pain interference scores (i.e., follow-up minus baseline). We used 10 covariates as potential confounders. RESULTS: Of the 302 analyzable patients, 93 (31%) were diagnosed as having a neuropathic component of the index pain. Multivariable linear regression analyses revealed that all the point estimates of regression coefficients at 1-, 2-, and 3-month follow-up were negative values; some were statistically significant. At 2-month follow-up, patients with a neuropathic component experienced greater reductions in their pain interference scores for walking ability (p = 0.048), normal work (p = 0.021), sleep (p = 0.001), and enjoyment of life (p = 0.010) than those without it. CONCLUSIONS: The presence of a neuropathic pain component predicted a greater reduction in pain interference after RT. Patients with neuropathic tumor-related pain should be offered the option of receiving palliative RT.
引用
- Saito T, Tomitaka E, Toya R, et al. A neuropathic pain component as a predictor of improvement in pain interference after radiotherapy for painful tumors: A secondary analysis of a prospective observational study. Clin Transl Radiat Oncol. 2018. PMID: 30148216. doi:10.1016/j.ctro.2018.08.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。